Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that ZOSTAVAX® (Zoster Vaccine Live), the company's vaccine to help prevent shingles, received the Prix Galien USA 2013 Award for Best Biotechnology Product.
“Merck is honored to have been chosen as a recipient of this prestigious award,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “This achievement is a testament to the remarkable contributions of everyone at Merck who played a role in helping to bring ZOSTAVAX to market.”
The Prix Galien Award recognizes the pharmaceutical industry's outstanding achievement in the development of new medicines. An internationally recognized award, the Prix Galien was founded in France in 1969 by French pharmacist Roland Mehl and is considered the highest accolade for pharmaceutical research and development.
This latest award for ZOSTAVAX is Merck's sixth Prix Galien USA award in seven years. The company was previously recognized for VICTRELIS (2012), ROTATEQ (2010), ISENTRESS (2008), and JANUVIA and GARDASIL (2007). In total, around the world, Merck has won the Prix Galien more than 30 times, making Merck one of the two most-awarded companies of all time.About Merck Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube. Forward-Looking Statement This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.